Current Hepatitis Reports

, Volume 12, Issue 2, pp 105–111

Stopping Therapy in HBeAg Negative Disease

Hepatitis B: Therapeutics (P Martin and WG Cooksley, Section Editors)

DOI: 10.1007/s11901-013-0167-5

Cite this article as:
Chan, W.K., Tan, S. & Mohamed, R. Curr Hepatitis Rep (2013) 12: 105. doi:10.1007/s11901-013-0167-5


Chronic hepatitis B infection confers a major risk of cirrhosis and hepatocellular carcinoma worldwide. The ultimate long-term goal of chronic hepatitis B therapy is to reduce morbidity and mortality related to liver disease progression. The ideal treatment endpoint is HBsAg seroconversion. As HBsAg clearance is rarely achieved, the short-term goal of therapy is maintained suppression of hepatitis B replication. For HBeAg-positive patients, durable HBeAg seroconversion with undetectable HBVDNA is a satisfactory intermediate end-point. For HBeAg-negative patients, the treatment endpoint remains unclear, hence, sustained suppression of HBV DNA level to low or undetectable levels is the optimal treatment response. Several studies in HBeAg-negative population have proposed that discontinuation of antiviral treatment can be considered if undetectable serum HBV DNA is demonstrated on three separate occasions at least 6 months apart. Preliminary data suggests that on-treatment HBsAg quantification may play a role as a predictor of sustained response off-therapy.


Chronic hepatitis BHBeAg-negative diseaseStopping therapyNucleos(t)ide analoguesPegylated interferon-α



chronic hepatitis B


hepatitis B e antigen


hepatocellular carcinoma

(ccc DNA)

covalently closed circular DNA

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Weng Kai Chan
    • 1
  • Soek-Siam Tan
    • 2
  • Rosmawati Mohamed
    • 3
  1. 1.Department of MedicineKuala Lumpur General HospitalKuala LumpurMalaysia
  2. 2.Department of HepatologySelayang HospitalBatu CavesMalaysia
  3. 3.Department of MedicineFaculty of Medicine, University of MalayaKuala LumpurMalaysia